We report the results of a single-arm, open-label, phase 2 nonrandomized controlled trial (Atezolizumab Plus Bevacizumab in First-Line NSCLC Patients [TELMA]) that evaluated the efficacy of atezolizumab in combination with bevacizumab as first-line treatment for patients with locally advanced or metastatic nonsquamous NSCLC with high TMB (≥10 mut/Mb or ≥16 mut/mB in tissue or blood samples, respectively) and no EGFR or ALK alterations. This evidence concerns the gene ALK and non-small cell lung carcinoma.